PLoS ONE · 2014 · 51 citations · 27 references
Life SciencesImmunologyPharmacotherapyGene ExpressionImmunoregulationInflammationInflammatory SignalingMultiple SclerosisMultiple Sclerosis PharmacotherapyNeuroinflammationRegulatory T CellsT Cell BiologyAnti-inflammatory MechanismsCd4 Positive T CellsCd4 T Cell ActivationFingolimod TherapyMultiple Sclerosis ImmunopathogenesisMultiple Sclerosis TherapyPeripheral Regulatory T CellsRelapsing-remitting Multiple Sclerosis Treatment
BACKGROUND: Multiple sclerosis (MS) likely results from an imbalance between regulatory and inflammatory immune processes. CD39 is an ectoenzyme that cleaves ATP to AMP and has been suggested as a novel regulatory T cells (Treg) marker. As ATP has numerous proinflammatory effects, its degradation by CD39 has anti-inflammatory influence. The purpose of this study was to explore regulatory and inflammatory mechanisms activated in fingolimod treated MS patients. METHODS AND FINDINGS: Peripheral blood mononuclear cells (PBMCs) were isolated from relapsing-remitting MS patients before starting fingolimod and three months after therapy start. mRNA expression was assessed in ex vivo PBMCs. The proportions of CD8, B cells, CD4 and CD39-expressing cells were analysed by flow cytometry. Treg proportion was quantified by flow cytometry and methylation-specific qPCR. Fingolimod treatment increased mRNA levels of CD39, AHR and CYP1B1 but decreased mRNA expression of IL-17, IL-22 and FOXP3 mRNA in PBMCs. B cells, CD4+ cells and Treg proportions were significantly reduced by this treatment, but remaining CD4+ T cells were enriched in FOXP3+ cells and in CD39-expressing Tregs. CONCLUSIONS: In addition to the decrease in circulating CD4+ T cells and CD19+ B cells, our findings highlight additional immunoregulatory mechanisms induced by fingolimod.
27
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
Stephen Sawcer, Maria Ban, Anu Kemppinen et al. · Nature · 2011 · 2.7K citations · Full text
Life Sciences, Immunology, Neurology +17
Control of Treg and TH17 cell differentiation by the aryl hydrocarbon receptor
Francisco J. Quintana, Alexandre S. Basso, Antonio Iglesias et al. · Nature · 2008 · 1.8K citations
The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins
Marc Veldhoen, Keiji Hirota, Astrid M. Westendorf et al. · Nature · 2008 · 1.6K citations · Full text